Robert, C., Sacco, J. J., Muñoz-Couselo, E., Schadendorf, D., In, G. K., Beasley, G. M., … Wong, M. K. (2025). 1644P Efficacy and safety of RP1 plus nivolumab in patients with advanced anti–PD-1-failed acral melanoma. In Annals of Oncology (Vol. 36, pp. S975–S976). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.2272

Robert, C., J. J. Sacco, E. Muñoz-Couselo, D. Schadendorf, G. K. In, G. M. Beasley, J. J. Niu, et al. “1644P Efficacy and safety of RP1 plus nivolumab in patients with advanced anti–PD-1-failed acral melanoma.” In Annals of Oncology, 36:S975–76. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.2272.

Robert C, Sacco JJ, Muñoz-Couselo E, Schadendorf D, In GK, Beasley GM, et al. 1644P Efficacy and safety of RP1 plus nivolumab in patients with advanced anti–PD-1-failed acral melanoma. In: Annals of Oncology. Elsevier BV; 2025. p. S975–6.

Robert, C., et al. “1644P Efficacy and safety of RP1 plus nivolumab in patients with advanced anti–PD-1-failed acral melanoma.” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S975–76. Crossref, doi:10.1016/j.annonc.2025.08.2272.

Robert C, Sacco JJ, Muñoz-Couselo E, Schadendorf D, In GK, Beasley GM, Niu JJ, Chmielowski B, Wise-draper TM, Milhem MM, Bowles TL, Tsai KK, Lebbe C, Gaudy Marqueste C, Samson A, Zhu J, Viana M, Hou JW, Wong MK. 1644P Efficacy and safety of RP1 plus nivolumab in patients with advanced anti–PD-1-failed acral melanoma. Annals of Oncology. Elsevier BV; 2025. p. S975–S976.